An antibiotic already in use in Europe to treat pneumonia controlled deadly bloodstream infections with Staphylococcus aureus bacteria just as effectively as the most powerful antibiotic currently in use, according to data from a late-stage trial. Ceftobiprole from Swiss drugmaker Basilea Pharmaceutica appeared to be equally effective as the older drug daptomycin in the roughly one-in-four patients who had particularly difficult to treat methicillin-resistant S. aureus (MRSA) infections, researchers reported on Wednesday in The New England Journal of Medicine.
By Nancy Lapid (Reuters) - An antibiotic already in use in Europe to treat pneumonia controlled deadly bloodstream infections with Staphylococcus aure.
An antibiotic already in use in Europe to treat pneumonia controlled deadly bloodstream infections with Staphylococcus aureus bacteria just as effectively as the most powerful antibiotic currently.
A scientific journey decades in the making at Duke University has found a new antibiotic strategy to defeat gram-negative bacteria like Salmonella, Pseudomonas and E. coli, the culprits in many urinary tract infections (UTIs).
A scientific journey decades in the making has found a new antibiotic strategy to defeat gram-negative bacteria like Salmonella, Pseudomonas and E. coli, the culprits in many urinary tract infections. The synthetic molecule works fast and is durable. It interferes with synthesis of the bacterial outer membrane by jamming an enzyme. When tested against a clinical collection of 285 bacterial strains, including some that were highly resistant to commercial antibiotics, it killed them all.